Patent · US Active

Method for quantitatively determining a therapeutic TNF-alpha inhibitor

US11953503B2 · kind B2 · utility

0Cited by

3References

9Claims

0Family size

Assignee

Siemens Healthcare Diagnostics Products GmbH · DE

Inventors

Harald Althaus · Wetter, DE
Thorsten Keller · Neupotz, DE

Key dates

Filing date	Jan 14, 2019
Grant date	Apr 9, 2024
Priority date	—
Expiry date	Mar 23, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/525
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.